Cryo-Cell International Reports Slight Revenue Decline and Increased Net Income for Nine Months Ended August 31, 2026

Cryo-Cell International, Inc. reported its financial results for the third quarter and nine months ended August 31, 2026, revealing a slight decline in revenue compared to the previous year. Total revenue for the nine-month period was $23.3 million, down from $23.7 million in the same period of 2025. The decrease was primarily attributed to a 15% drop in the number of new domestic cord blood specimens processed, although there was a 3% increase in recurring annual storage fee revenue. For the third quarter alone, revenue remained relatively stable at $7.8 million, compared to $7.8 million in the prior year.

The company's net income for the nine months ended August 31, 2026, was $1.9 million, an increase from $1.4 million in the same period last year. This resulted in a net income per share of $0.23, compared to $0.17 for the previous year. The increase in profitability was supported by a reduction in costs, with total costs and expenses decreasing to $19.1 million from $19.3 million in the prior year. Notably, the cost of sales fell by 12% to $4.9 million, reflecting the lower volume of new specimens processed.

Operationally, Cryo-Cell's customer base remains strong, with over 250,000 cord blood and cord tissue specimens stored. The company has also expanded its service offerings, including the introduction of its ExtraVault service, which provides cold storage solutions for biopharmaceutical companies. The company’s total assets increased to $62.3 million as of August 31, 2026, up from $61.7 million at the end of November 2025, driven by an increase in cash and cash equivalents, which rose to $1.4 million from $319,031.

Strategically, Cryo-Cell has faced challenges related to its Patent and Technology License Agreement with Duke University, which has been a significant focus of its business expansion plans. The company filed for arbitration against Duke, alleging fraudulent inducement and breach of contract, which has led to a pause in its plans for the Cryo-Cell Institute for Cellular Therapies. The outcome of this arbitration could significantly impact the company's future operations and financial needs.

Looking ahead, Cryo-Cell anticipates that its cash reserves, marketable securities, and cash flows from operations will be sufficient to meet its needs for at least the next 12 months. However, the company remains cautious about its future investments, particularly in relation to the Duke License Agreement, and may require additional financing depending on the arbitration's outcome. The company continues to focus on increasing revenues from its core services while managing expenses effectively.